Drug reps today are facing an increasingly strong imperative to depart from traditional promotional activities simply aimed at getting doctors’ prescriptions. For these reps to shift to communications focusing on proper drug use, the key will be their performance reviews.…
HOME > BUSINESS
BUSINESS
- Non-Japanese Players Nab 60% of Top 20 Company Sales, IQVIA Data Show
February 25, 2020
- “Tender Process Needs to Be Improved” in Response to Bid-Rigging Scandal by Top 4 Wholesalers: Hospital Management Advisor
February 25, 2020
- Astellas, MSD Follow Suit to Boost Measures to Protect Employees from Coronavirus Infection
February 21, 2020
- Takeda Vaults to 9th in Global Pharma Ranking after Shire Buy, Roche Tops List: Jiho Tally
February 21, 2020
- Kyowa Kirin Initiates Japan PI Trial of Automated Injection Device for G-Lasta
February 21, 2020
- GSK Japan Resurrects “Sales” for Rep Performance Review, Doctor Payments; Critics Say It’s a Rollback
February 20, 2020
- Kowa Launches Japan PIII Study of Glanatec/Brimonidine Combo for Glaucoma, Ocular Hypertension
February 20, 2020
- Drug Makers in Japan Urging Staffers to Work at Home, Shun Rush-Hour Commuting amid Coronavirus Fears
February 19, 2020
- Japan Pharma Market Logs 1st Growth in 3 Years in 2019, Keytruda Is the Best-Seller: IQVIA
February 19, 2020
- Takeda’s Entyvio SC Form Hits Main Goal in PIII Crohn’s Disease Study
February 18, 2020
- HIV Med Pifeltro Now Available in Japan: MSD
February 18, 2020
- Chugai, Sanofi Wind Up License Deal for Apleway; Kowa to Get MA
February 18, 2020
- ASKA Takes Over Uterine Fibroids Drug Relumina from Takeda
February 18, 2020
- Dovobet Foam Formulation Filed in Japan: LEO Pharma/Kyowa Kirin
February 17, 2020
- Tecentriq-Avastin Combo Filed for HCC in Japan: Chugai
February 17, 2020
- Otsuka’s Pharma Sales Surge as Tolvaptan Grows Six-Fold in North America
February 17, 2020
- Teijin Pharma Set to Boost Partnerships in R&D, Seeking Licensee for Diabetic Nephropathy Drug: President
February 17, 2020
- Eisai Pulls Belviq from US Market after FDA Flags Cancer Risks
February 17, 2020
- Chugai, US Foundation Medicine Team Up with NCC for Blood-Based Genomic Testing
February 17, 2020
- StemRIM to Set Up Collaborative Lab in Osaka University
February 14, 2020
ページ
Eisai is aiming to notch up a compound annual growth rate (CAGR) of 20% over FY2020-2025 under its five-year business plan. The primary driver will certainly be Lenvima (lenvatinib), a fast-growing cancer drug that has earned an up-to-US$5.76 billion alliance…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Look into the heart of every successful company, the businesses that have made a real impact on the world, and you’ll notice they all share a common trait.The people. But not just any people, as Jim Collins famously said…“People are…